THE ARTEMISININ ENTERPRISE - GHDonline

More documents

Recommendations

Info

RBx 11160 Next Generation OZ % of Initial Remaining 100 90 80 70 60 50 40 30 20 infected blood (1% parasitemia) healthy blood % of Initial Remaining 100 90 80 70 60 50 40 30 20 infected blood (1% parasitemia) healthy blood 10 10 0 60 120 180 2400 60 120 180 240 Time (min) Time (min) Figure 2. Comparison of the stability of first and second generation OZ compounds in healthy and parasite‐infected blood From studies in P. berghei‐infected mice, compounds from the second generation OZ project have demonstrated 100% survival out to 30 days, and single‐dose cures following oral doses of 30mg/kg. Furthermore, several compounds demonstrate 100% prophylaxis and superiority to mefloquine (Lariam®). The Next Generation OZ will shortly be going into healthy volunteers with the hope for launch at the end of 2015. 18
4. The malaria context Burden of malaria ʺTreatment is a key part of the GMAP. The GMAP is very ambitious ‐ and all these technologies in the pipeline can contribute to meeting its targetsʺ ‐ Professor Awa Coll‐Seck, Executive Director, Roll Back Malaria Partnership The World Malaria Report 2008 highlights that in 2006 there were between 189 and 327 million cases of malaria annually leading to at least 880,000 deaths, 85% of which are children in Sub‐Saharan Africa. Children under five, pregnant women, malnourished people or others with compromised or underdeveloped immune systems are at the greatest risk of acquiring severe malaria and succumbing to the disease. The immunity of populations, including adults, where malaria strikes only every so many years falls back to very low levels or to zero, making them extremely vulnerable each time again, leading to murderous epidemics. It is estimated that a child dies from malaria every thirty seconds. In sub‐Saharan Africa malaria is responsible for nearly one in five deaths in children under five. In addition to its impact on health care, the malaria burden extends to the economies and families of the poorest countries. Malaria is estimated to cost sub‐Saharan Africa approximately 1.3% of its Gross Domestic Product (GDP), or about USD 12 billion in direct losses each year resulting from illness, treatment and premature death. 1 If malaria had been eliminated from sub‐Saharan Africa before 1980, the regionʹs GDP in 2000 would likely have been 32% higher, or an increase from some USD 300 to USD 400 billion. 2 19
Page 1 and 2: THE ARTEMISININ ENTERPRISE REPORT o
Page 3 and 4: 1. Executive Summary The World Mala
Page 5 and 6: An effective, joined‐up communica
Page 7 and 8: artemisinin from plant material by
Page 9 and 10: 3. The Artemisinin Enterprise Partn
Page 11 and 12: Useful genetic diversity does not a
Page 13 and 14: Benefits of new high‐yielding var
Page 15 and 16: Partnership has been a key componen
Page 17: Synthetic peroxides The first synth
Page 21 and 22: Global targets and tools The Global
Page 23 and 24: The development of Artemisinin Comb
Page 25 and 26: Currently, some seed selection for
Page 27 and 28: ACT and artemisinin market size ‐
Page 29 and 30: Demand versus purchase orders for A
Page 31 and 32: 5. The contributions of the AE tech
Page 33 and 34: Project delivery timelines The timi
Page 35 and 36: 6. Conference recommendations to th
Page 37 and 38: Assess the impact of new variety de
Page 39 and 40: the use of counterfeit drugs, monot
Page 41 and 42: Session 1: Opening and keynote lect
Page 43 and 44: Day 3 October 10 Session 5: Breakou
Page 45 and 46: Philippe Farabolini sanofi‐aventi
Page 47 and 48: Annex 3. Abbreviations Active Pharm

THE ARTEMISININ ENTERPRISE - GHDonline

Create successful ePaper yourself

Delete template?

Save as template?